_pdf.png)
ACTIVE STUDIES
HNCIG-1
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS). Open through NCRI.
HNCIG-2/EORTC 1420
Study Assessing the "Best of" Radiotherapy vs the "Best of" Surgery in Patients with Oropharyngeal Carcinoma (Best of). Open and recruiting through EORTC, SAKK, and NCRI UK.
HNCIG-3/COMPARE
Phase III Randomized Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-Risk Oropharyngeal Cancer. Open through NCRI, open at Irish CTG.
HNCIG-5/NRG HN001
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA. Coordinated by NRG Oncology. Accrued 284 with participating sites from the HKNPC study group, Singapore, and Taiwanese sites.
HNCIG-7/EPIC-OPC
International multicentre study seeking to quantify the extent of discordance between p16 and HPV in oropharyngeal cancer, and its prognostic implications
HNCIG-8/HNC TACTIC
HNCIG-9/Guidelines
pending
HNCIG-10/Harmonization of Endpoints
This is an international collaboration which is reviewing recent publications and clinical trials to evaluate differences in endpoints used to assess locoregionally advanced and recurrent/metastatic head and neck cancers, with the goal of improving the definition and harmonization of endpoints.
HNCIG-11/iENE Delphi Consensus
Working to develop international consensus recommendations on terminology, methodology, modalities, and classification systems for identifying radiographic extracapsular nodal extension.
HNCIG-12/pENE Delphi Consensus
Working to develop international consensus recommendations on terminology, methodology, and importance of various degrees of pathologic extracapsular nodal extension.
HNCIG-13/Multi-Site Collaboration on Extranodal Extension
Multi-site study of data from patients treated for head and neck cancer, to examine and correlate findings of pathologic and radiologic ENE and to assess the significance of iENE as a prognostic factor.
HNCIG-14/EORTC 1206
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer.
COMPLETED STUDIES
HNCIG-6/NRG HN002
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer (Published)
HNCIG-4/DE-ESCALATE
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC (De-ESCALaTE). Open through NCRI, Cancer Trials Ireland. (Published)
EORTC 1219
AF CRT +/- Nimorazole in HNSCC
EORTC 3311
Transoral Surgery Followed by Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
GORTEC TPEXTREME
Platinum-Cetuximab Combined With Docetaxel or 5FU in Patients With Recurrent/Metastatic HNSCC.